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Early death (ED), defined as death within the first treatment cycle,
was more frequently observed in our two latest randomized trials
of combination chemotherapy in unselected patients with small-
cell lung cancer (SCLC) compared with our previous trials from
the Copenhagen Lung Cancer Group. A total of 12.6% of all
patients died during the first treatment cycle, 6.7% in limited
disease patients and 18.9% in extensive disease. In our preceding
trials, early death was encountered in only 4.2% of all the patients,
3.6% in limited disease and 4.8% in extensive disease.
The increased frequency of early death could be caused by
either inferior or more toxic treatment or by an increased number
of patients with poor prognosis. However, a recent analysis of our
treatment outcome during two decades did not encounter stage
migration or change in the distribution of prognostic factors over
time (Lassen et al, 1998). According to the International
Association for the Study on Lung Cancer (IASLC), toxic death,
defined as death during septic episodes, should not exceed 5%
(Kristjansen et al, 1990). The risk of early death caused by toxi-
city, i.e. infections, bleeding episodes etc., may be reduced by
identification of high-risk patients. They should primarily be
found among those with poor prognostic factors, such as extensive
stage of disease, poor performance status (PS), high age and high
serum lactate dehydrogenase (LDH). Prompted by the observed
increased frequency of early death, the present analysis was
carried out focusing on treatment intensity and risk factors for
early death, especially early toxic death, in patients with SCLC.
PATIENTS AND METHODS
Treatment intensity
The rates of grade IV leucopenia (< 1000 white blood cells mm—3)
in the recent trials with a higher rate of early death were compared
with the trials conducted from 1976 to 1981. The details of these
trials have previously been published (ﬂsterlind et al, 1983, 1986,
1991; Hirsch et al, 1987). Early death was defined as death within
the first treatment cycle (4 weeks). Early toxic death (ETD) was
defined as early death during episodes with neutropenia and fever,
and early non-toxic death (ENTD) was defined as early death in all
other instances including progression and concurrent diseases.
Patients with neutropenia, but without fever or other signs of
infection, were allocated to the ENTD group. Data were obtained
from a database of patient records and clinical report forms of
trials conducted in our group. A detailed comparison of patient
characteristics during this time have recently been performed and
published (Lassen et al, 1997).
Prognostic factors
A detailed analysis of patients included from 1981 to 1991 in our
two latest randomized trials was performed. All trials were
conducted jointly at Rigshospitalet and Bispebjerg Hospital,
Copenhagen, Herlev University Hospital and Hiller¿d Sygehus,
Denmark, and Renstr￿mska Hospital, Gothenburg, Sweden. The
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Summary Based on an increased frequency of early death (death within the first treatment cycle) in our two latest randomized trials of
combination chemotherapy in small-cell lung cancer (SCLC), we wanted to identify patients at risk of early non-toxic death (ENTD) and early
toxic death (ETD). Data were stored in a database and logistic regression analyses were performed to identify predictive factors for early
death. During the first cycle, 118 out of 937 patients (12.6%) died. In 38 patients (4%), the cause of death was sepsis. Significant risk factors
were age, performance status (PS), lactate dehydrogenase (LDH) and treatment with epipodophyllotoxins and platinum in the first cycle (EP).
Risk factors for ENTD were age, PS and LDH. Extensive stage had a hazard ratio of 1.9 (P = 0.07). Risk factors for ETD were EP, PS and
LDH, whereas age and stage were not. For EP, the hazard ratio was as high as 6.7 (P = 0.0001). We introduced a simple prognostic algorithm
including performance status, LDH and age. Using a prognostic algorithm to exclude poor-risk patients from trials, we could minimize early
death, improve long-term survival and increase the survival differences between different regimens. We suggest that other groups evaluate
our algorithm and exclude poor prognosis patients from trials of dose intensification.
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Denmarkstudies included a total of 941 consecutive patients, and 937
patients were evaluable for this analysis (Pedersen et al, 1987;
Lassen et al, 1996).
There were no limitations for inclusion into the studies with
respect to PS, the presence of CNS or bone marrow metastases,
liver function tests etc., resulting in a considerably higher fraction
of patients with poor prognostic factors. Table 1 describes the
study design of the two trials.
All data were stored in a database, and the association between
treatment, pretreatment factors and early death was analysed with
special reference to toxic deaths. The factors included stage, liver,
bone marrow and brain metastases, gender, age, PS and biochem-
ical and haematological variables. Pretreatment characteristics of
ETD and ENTD patients were compared with the characteristics
of those who survived the first 4 weeks (controls) to identify prog-
nostic factors.
Statistical analysis
Data were analysed using an interactive program (SPSS, statistical
package, 1995). Patient characteristics were compared using c2
test for discrete data, and the Kruskal—Wallis test for ordinal scale
variables and continuous non-parametric data. Logistic regression
analysis was used to analyse factors of prognostic significance for
events such as early death, ENTD and ETD. In the analyses, LDH
was categorized according to the multiplicity of upper normal
levels (450 units l—1) and age was dichotomized to <65 or ‡65
years. Survival analysis was calculated by the Kaplan—Meier
method, and groups were compared for statistically significant
difference using the log-rank method.
RESULTS
Treatment comparison
The frequencies of ED and ETD were less than 3.4% and 1.4%,
respectively, in our trials performed in 1976—81 (ﬂsterlind et al,
1983, 1986, 1991). In a later randomized trial, these figures
changed in a treatment arm with early inclusion of etoposide, based
on in vivo cell cyclus analysis. In this arm, ED and ETD were
encountered in 19% and 10%, respectively, and grade IV leuco-
penia was observed in 51% of the patients (Hirsch et al, 1987).
Table 2 shows the distribution of grade IV leucopenia, median
white blood cell (WBC) nadir, ENTD and ETD in the different
treatment regimens of the trials. The combination of epipodophyl-
lotoxins and platinum (EP) in the induction regimens resulted in an
increased number of toxic deaths (P = 0.0002), whereas treatment
had no significant impact on ENTD. The sequential arm in the first
trial was more myelotoxic than the other treatment arms (median
WBC nadir 760 mm—3, P < 0.001). In the latest trial, ETD was more
frequently observed in the EP regimens even though low median
WBC nadir and grade IV leucopenia were more pronounced in the
non-EP regimens. The duration of the leucopenic episodes have not
been recorded. In general, significantly more ETD occurred among
patients receiving EP (P = 0.04).
When early death patients were excluded from the two trials, the
outcome was significantly changed. In the 1981—85 trial, the
survival inferiority of the EP regimens disappeared and no
survival difference was present (P = 0.15). In the 1985—91 trial,
the significant superiority (P = 0.04) of the EP regimens increased
(P = 0.002), as reflected by a difference in median survival of 2
months compared with the previous 1 month. Figure 1 compares
the survival curves of all patients, early deaths and the patients
surviving the first 4 weeks of treatment.
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Table 1 Summary of treatment regimens in trial LU-8109 and LU-8501
Trial (reference) Arm n Regimen
1981–85 I 152 LCMV alternating with DEV
(Pedersen et al, 1987) II 153 Arm I alternating with PvdH
III 150 LCVE alternating with LCVP,
LCVD, LCVVd, LCVM and LCVH
1985–91 I 162 PTV alternating with arm III
(Lassen et al, 1996) II 161 JTV alternating with arm III
III 159 CLV alternating with EDV and PVdH
All regimens administered in 4-week cycles. L, CCNU; C, cyclophosphamide;
M, methotrexate; V, vincristine; D, doxorubicin; E, etoposide; P, cisplatin; Vd,
vindesine; H, hexamethylmelamine; T, teniposide; J, carboplatin.
Table 2 Numbers of early deaths in relation to treatment regimen
Leucopenia WBCa nadir
Treatment arm ENTDb (%) ETDc (%) grade IV (%) median (mm–3)
1981–85 trial
(Pedersen et al, 1987)
I, n = 152 9 1 23 1700
II, n = 153 5 2 29 1500
IIIa, n = 150 9 9 61 760d
1985–91 trial
(Lassen et al, 1996) 1800
Ia, n = 162 10 6 22
IIa, n = 161 8 5 21 1600
III, n = 159 10 1 37 1300
ENTD, early non-toxic death; ETD, early toxic death; WBC, white blood cell
counts. aEpipodophyllotoxins and platinum during first cycle (EP); bENTD,
EP vs non-EP, P = n.s.; cETD, EP vs non-EP, P = 0.0002; dWBC nadir,
P < 0.0001, Mann–Whitney.
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Figure 1 Kaplan–Meier survival curve of 937 patients with SCLC (¾),
median survival 309 days (95% CI 289–329), compared with the survival
curve when all early deaths, defined as death during the first 4 weeks of
chemotherapy, were excluded (- -), median survival 344 days (95% CI
325–363)Prognostic factors
A total of 941 patients were included in the two trials from 1981 to
1991, and 932 patients were evaluable for the analysis of prog-
nostic factors. One hundred and eighteen patients died during the
first 4 weeks after start of treatment (12.6%). The most frequent
cause of death was disease progression, but whether a patient died
from progression or concurrent diseases could not always be
defined because some patients died at home and because autopsy
was not performed routinely. A majority of ED occurred during the
second week after initiation of chemotherapy when blood cell
counts were at the lowest level, and ETD was recorded in 38
patients (4%). In some instances, ED may have been caused by a
combination of toxicity, progression or concurrent diseases. Table
3 shows the pretreatment characteristics of ENTD patients, ETD
patients and the control group. Extensive disease and elevated
liver enzymes were significantly more frequent among patients
who died within the first 4 weeks, whereas the sex ratio was equal
between the groups. Also, poor PS was more frequently observed
in early deaths. However, 27% of ETD had initial PS 1 and 27%
had initial PS 2. The median age and the median values of lactate
dehydrogenase (LDH) and alkaline phosphatase (AP) were signif-
icantly higher in patients dying early (Kruskal—Wallis). These
factors were equally distributed between the ENTD and ETD
group, except extensive stage which was less frequently observed
with ETD (P = 0.05, c2 test).
A variable indicating induction regimens containing
epipodophyllotoxins and platinum was introduced (EP). This vari-
able was added to the statistically significant variables from the
univariate analysis in subsequent logistic regression analyses of
factors with prognostic impact on early death, ETD and ENTD
(Table 4). Significant risk factors of early death were high age,
poor performance status, elevated LDH and EP treatment. High
age, poor performance status and elevated LDH were statistically
significant risk factors for ENTD. Extensive stage of disease
resulted in a hazard ratio of 1.9, but the confidence interval did not
reach significance (P = 0.07). EP had no influence on ENTD, and
age was not a significant factor in a separate analysis of limited
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Table 3 Pretreatment characteristics for early deaths and controls
ENTD ETD Controls
Factor n =8 0 n =3 8 n = 819 Significance
Age (median, years) 65 64 61 P<0.0005c
Men/women (%) 63/37 66/34 65/36 NSb
Stage L/E (%)a 24/76 42/58 58/42 P<0.0005b
PS (%)
WHO 0 3 3 23 P<0.0005c
WHO 1 19 27 44
WHO 2 24 27 19
WHO 3 33 24 10
WHO 4 21 19 4
AP (median, U 1–1) 444 293 217 P=0.01c
LDH (median, U 1–1) 1030 860 436 P=0.0005c
Liver metastases (%) 38 40 18 P<0.005b
Bone marrow metastases (%) 30 35 14
Brain metastases (%) 9 5 3
L/E, limited/extensive stage; PS, performance status; ENTD, early non-toxic
deaths; ETD, early toxic deaths; AP, alkaline phosphatase; LDH, lactate
dehydrogenase. aStage: ENTD vs ETD, P = 0.05; bchi-squared test;
cKruskal–Wallis test.
Table 4 Logistic regression analysis of factors of prognostic significance for
early death (ED), early non-toxic death (ENTD) and early toxic death (ETD)
Hazard ratio 95% CI Significance
Early death
Age 2.21 1.32–3.71 0.003
PS 2.06 1.66–2.56 <0.00005
Stage 1.15 0.65–2.03 0.6
LDH 1.62 1.35–1.95 <0.00005
EP 2.32 1.42–3.79 0.0008
Early non-toxic death
Age 2.58 1.38–4.83 0.003
PS 1.88 1.46–2.42 <0.00005
Stage 1.92 0.94–3.92 0.07
LDH 1.45 1.18–1.78 0.0004
EP 1.15 0.66–2.00 0.6
Early toxic death
Age 1.36 0.65–2.82 >0.4
PS 1.86 1.34–2.57 0.0002
Stage 0.55 0.23–1.32 0.2
LDH 1.59 1.20–2.10 0.001
EP 6.66 2.66–16.70 0.0001
PS, performance status (WHO); LDH, lactate dehydrogenase; EP,
epipodophyllotoxins and platinum during first cycle; CI, confidence interval.
Table 5 Algorithm for predicting risk of early death and poor prognosis
Characteristic Score
Performance status 3 or 4 2
LDH > twice upper normal level 1
Age ³65 years 1
Sum score ³2 allocates patients to risk group. LDH, lactate dehydrogenase;
upper normal level 450 U l–1.
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Figure 2 Kaplan–Meier survival curve of all 937 patients with SCLC (¾),
median survival 309 days (95% CI 289–329), compared with the favourable
prognosis group, n = 737 (– - –) median survival 351 days (95% CI 331–371),
and the poor prognosis group, defined as patients with PS 3 or 4 or LDH
> 900 units l–1 and age ³65 years, n = 200 (- - -) median survival 133 days
(95% CI 86–180)disease only. The same analysis of ETD showed that poor PS and
elevated LDH were statistically significant. EP was a powerful
factor of ETD with a hazard ratio of 6.7. Neither bone marrow nor
liver or brain metastases were independent predictive factors for
early death or early toxic death. The patients with PS 1 or 2 had
significantly increased hazard ratios for elevated LDH, age ‡65
and EP regimens (hazard ratios 1.7, 2.4 and 5.3 respectively).
Based on hazards from the analyses of both ENTD and ETD, a
prognostic algorithm for early death was introduced. The major
prognostic factors were weighted according to the hazard. PS 3 or
4 scored 2 points, LDH > twice upper normal level and age >65
years each scored 1 point. Stage was not a significant prognostic
factor for ED and was not included in the algorithm. Patients were
allocated to the poor prognosis group if the total score was 2 points
or more (Table 5). The poor prognosis group included patients
with PS 3 or 4 or LDH > twice upper normal level and age ‡65.
With this algorithm, a majority of EDs could be excluded; this
group accounted for 21% of the patients. The remaining 79% of
the patients were allocated to a favourable prognosis group and a
survival analysis was performed. In the trial from 1981 to 1985,
the inferiority of the EP regimen was reduced after exclusion of
the majority of early deaths, but it was still significant (P = 0.03).
In the 1985—91 trial, the superiority of EP compared with non-EP
regimens became more pronounced when the analysis only
included the favourable prognosis patients (median survival 376
days vs 310 days respectively, P = 0.03). In the favourable group,
3-year survival was 11.4% compared with 7.8% among all patients
receiving EP. These changes were comparable to the changes
resulting when early deaths were excluded from the survival
analyses. Figure 2 compares the survival curves for all patients,
the favourable and the poor prognosis groups.
In the poor prognosis group, median survival was 133 days, and
2- and 3-year survival rates were 4.5% and 2.0% respectively. In
this group of patients, the frequency of early death was 33%, and
among the patients receiving EP the frequency was 41%.
DISCUSSION
Previous studies of early death have identified stage, PS and liver
enzymes as significant prognostic factors, but also epipodophyllo-
toxins have been proposed to be responsible for an increased risk
of early toxic death (Morittu et al, 1989). It has been suggested that
this possibly could be caused by an association between hepatic
metastases, compromised liver function and elimination of etopo-
side (Pfluger et al, 1987; Morittu et al, 1989). However, a discrim-
ination between early death due to progression and early death due
to infection was not made in these studies. Other studies have
focused on toxic death alone. Radford et al (1993) identified
factors predicting septic complications in an analysis of 382
patients and derived a prognostic index including PS ‡3, age >50
and three or more drugs. However, the Radford et al (1993) study
did not discriminate between early or later toxicity. Another large
analysis of 2196 patients modified the Radford index by omitting
age and including WBC ‡10 000 mm—3. In addition, PS was modi-
fied to ‡2 and the number of drugs increased to four or more.
Patients dying from sepsis were not recorded and the analysis was
exclusively based on excess death rates during the first treatment
cycle (Stephens et al, 1994).
The fact that ETD was more frequent in the EP regimens in our
latest trial despite the fact that leucopenia was more pronounced in
the control regimen indicates the complexity of this problem. The
schedule of administration of epipodophyllotoxins has previously
been shown to be important for outcome. Based on in vivo cell
kinetic observations, it has been shown that etoposide has maximal
activity against cells in the S and G2 phases (Kalwinsky et al,
1983). In most regimens, epipodophyllotoxins, therefore, are
administered for 3—5 days early in each cycle. This was also the
case in our regimens. This could possibly result in nadir periods of
longer duration compared with regimens in which the drugs are
administered in 1 day. Unfortunately, our haematological surveil-
lance did not include daily blood cell counts. This was only the
case when grade IV toxicity had resulted in hospitalization of the
patients. Therefore, a comparison of nadir durations among the
different regimens could not be performed.
Risk of early death due to infection seems to be more indepen-
dent of stage, and fatal toxicity occurred in both stages. Increased
LDH was an independent prognostic factor, presumably related to
tumour burden rather than to hepatic function. PS was found to be
the most powerful risk factor of both toxic and non-toxic early
death. Stratification for PS and LDH is extremely important in
both disease stages because these patients have an increased risk
of early toxic death when treated with extraordinary myelotoxic
combination chemotherapy. It is noteworthy that more than 50%
of ETD occurred among patients with PS 1 or 2. A majority of
these patients had increased LDH and were more than 65 years
old. Therefore, it is difficult to propose a simple algorithm
predicting risk of ETD. Patients with PS 1 in general have a
favourable prognosis and should be included in clinical trials. Our
data suggest that good performance patients should receive
increased haematological surveillance if they are more than 65
years old or have elevated LDH. In addition, treatment with
colony-stimulating factors could possibly reduce the risk of ETD
in this group, but this needs further evaluation in prospective clin-
ical trials. If the patients are older than or equal to 65 years and
have moderately elevated LDH, they should be excluded from
trials with potent myelosuppressive agents.
Most phase II and III trials of high-dose chemotherapy and dose
intensification have been disappointing with regard to survival
(Stahel et al, 1984; Johnson et al, 1987; Jackson et al, 1988; Klasa
et al, 1991; Katakami et al, 1996; Fetscher et al, 1997; Murray et
al, 1997). Most of these trials only included patients with good
performance status and thereby excluded approximately 15% of
the patients. If patients with other poor prognostic factors had been
excluded, the results might have been in favour of treatment inten-
sification. Epipodophyllotoxins can safety be administered to
elderly patients (Bork et al, 1991, 1997). The risk of toxic death is
correlated to dose intensity and scheduling with other agents.
According to this and other similar analyses, the goal for treatment
of patients with poor prognosis primarily is palliative. It should not
be too intensive (Girling et al, 1996a), albeit monotherapy with
etoposide may be suboptimal (Girling et al, 1996b; Souhami et al,
1997) compared with intravenous combination chemotherapy. Our
analysis did not address how to treat such patients; epipodophyllo-
toxins and platinum are widely used, and dosage and scheduling
will always depend on a narrow balance between efficacy and
toxicity.
Our algorithm included predictive factors for both ENTD and
ETD. The frequency of early death among the excluded group of
patients was as high as 41% when receiving EP. We propose that
other groups use and evaluate our algorithm to exclude patients
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agents and trials with dose intensification or dose escalation.
Exclusion of such patients may reveal that dose intensification will
result in a significantly improved outcome. This should encourage
further randomized studies in SCLC in patients with a favourable
prognosis. These account for approximately 80% of the patients
who better tolerate intensive treatment, and an increased toxicity is
acceptable provided more patients become long-term survivors.
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